



June 2023

Genentech, Inc.
1 DNA Way
South San Francisco, CA 94080
USA

Dear Patient:

This letter is to inform you about an important change to the Gavreto™ (pralsetinib) label in the United States (U.S.).

Genentech, a member of the Roche Group, announced the decision to voluntarily withdraw Gavreto for the treatment of adults and children 12 years of age and older with advanced medullary thyroid cancer (MTC) or MTC that has spread who require a medicine by mouth or injection (systemic therapy) in the U.S.. This decision is not based on new safety or efficacy data, and does not affect other approved indications for Gavreto, including for the treatment of RET fusion-positive thyroid cancer and non-small cell lung cancer.

If you are currently receiving Gavreto for advanced medullary thyroid cancer (MTC) or MTC that has spread, you should talk to your doctor about what the withdrawal means for you and your current treatment. You should always discuss with your doctor the risks and the benefits of treatment with Gavreto.

The withdrawal of the MTC indication could mean that some insurers may no longer pay for Gavreto for this type of cancer. If you are concerned about insurance coverage, please contact Genentech for assistance. Genentech is committed to supporting patients who are currently benefiting from Gavreto therapy and may be facing obstacles to receiving treatment. If your insurance has changed, or you can't pay for your Genentech medicine, we may be able to help.

Please call the Genentech Patient Resource Center at 1-877-436-3683 and you will be connected to one of our patient support specialists who can help answer your questions.

We acknowledge and empathize with the challenging nature of this situation for you and your loved ones. Genentech's scientists, doctors and employees remain committed to advancing the scientific understanding of cancer and discovering new medicines.

This letter is not intended as a complete description of the benefits and risks related to the use of Gavreto. Please refer to the Patient Information (https://www.gene.com/download/pdf/gavreto_patientinfo.pdf) for more information in other indications.

Sincerely,

Nancy Yao, MD
Vice President
Chief Medical Partner, Oncology
U.S. Medical Affairs